bioAffinity Technologies ... (BIAFW)
0.19
-0.03 (-13.68%)
At close: Mar 31, 2025, 12:53 PM
bioAffinity Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Cash & Equivalents | 2.82M | 11.41M | 1.36M | 83.11K | 578.48K |
| Short-Term Investments | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 16.06K | 6K | 10.44K | 17.5K | 12.5K |
| Receivables | 811.67K | 10.49K | 1.53K | 1.53K | 1.53K |
| Inventory | 18.48K | 5.54K | 71.85K | 28.35K | n/a |
| Other Current Assets | 321.02K | 531.9K | 76.06K | 34.02K | 37.49K |
| Total Current Assets | 3.97M | 11.96M | 1.44M | 118.66K | 617.51K |
| Property-Plant & Equipment | 1.99M | 214.44K | 4.63K | 9.45K | 28.8K |
| Goodwill & Intangibles | 2.24M | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 4.25M | 220.44K | 15.07K | 26.95K | 41.3K |
| Total Assets | 8.22M | 12.18M | 1.45M | 145.6K | 658.81K |
| Account Payables | 604.79K | 345.04K | 230.41K | 191.39K | 103.42K |
| Deferred Revenue | 33.06K | n/a | n/a | n/a | n/a |
| Short-Term Debt | 460.17K | 251.75K | 11.2M | 9.95M | 4.01M |
| Other Current Liabilities | 1.15M | 541.89K | 1.6M | 976.1K | 579.93K |
| Total Current Liabilities | 2.25M | 1.14M | 13.04M | 11.12M | 4.69M |
| Long-Term Debt | 1.12M | n/a | 160.18K | 53.47K | n/a |
| Other Long-Term Liabilities | n/a | n/a | 4.04M | 4.04M | n/a |
| Total Long-Term Liabilities | 1.12M | 596.79K | 4.2M | 4.1M | n/a |
| Total Liabilities | 3.37M | 1.14M | 17.24M | 15.22M | 4.69M |
| Total Debt | 1.58M | 251.75K | 11.36M | 10.01M | 4.01M |
| Common Stock | 65.76K | 58.67K | 18.74K | 18.72K | 18.72K |
| Retained Earnings | -44.6M | -36.67M | -28.51M | -22.19M | -14.92M |
| Comprehensive Income | n/a | n/a | -4.04M | -4.04M | -18.72K |
| Shareholders Equity | 4.86M | 11.04M | -15.79M | -15.07M | -4.04M |
| Total Investments | n/a | n/a | n/a | n/a | n/a |